statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range...

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Biopharmaceutical Innovator Sees Significant Increases in Product Sales and Cash FlowRelated Stocks: XERS...

Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

This indicator may be signaling that XERS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Xeris Biopharma Holdings (XERS, $3.07) entered Downtrend as Momentum indicator drops below 0 level on Feb 29, 2024

This is a Bearish indicator signaling XERS's price could decline from here. Traders may explore shorting the stock or put options...

Xeris Biopharma Holdings (XERS, $3.02) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 28, 2024

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Watchers	10,226
52-Wk Low	$1.46
52-Wk High	$3.26

Volume	1.94M
52-Wk High	$3.26
52-Wk Low	$1.46

XERS Xeris Biopharma Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals